Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07913555

Oliceridine for Remifentanil-Induced Postoperative Hyperalgesia

Conditions: Postoperative Hyperalgesia

Sex: Female
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 130
Sponsor: Xingguo Xu

Location: Affiliated Hospital of Nantong University Nantong Jiangsu

Summary

Objective: To investigate the effect of oliceridine on remifentanil-induced postoperative hyperalgesia and to observe its effects on postoperative pain scores, quality of recovery, and adverse reactions.Methods: A total of 130 patients undergoing gynecological laparoscopic surgery under general anesthesia were enrolled and randomly assigned to either the oliceridine group (Group O) or the sufentanil group (Group S), with 65 patients in each group. Remifentanil was used for anesthesia maintenance in both groups. Before skin closure, patients received either 0.02 mg/kg oliceridine (Group O) or 0.1 μg/kg sufentanil (Group S) via intravenous injection. The primary outcome measure was the mechanical pain threshold around the incision at 6 h postoperatively. Secondary outcome measures included mechanical pain thresholds around the incision and on the non-dominant forearm at 30 min, 6 h, 24 h, and 48 h postoperatively; Numeric Rating Scale (NRS) pain scores; number of effective patient-controlled analgesia (PCA) compressions; incidence of rescue analgesia; 24 h postoperative Quality of Recovery-15 (QoR-15) score; extubation time; post-anesthesia care unit (PACU) stay duration; and incidence of adverse reactions within 48 h postoperatively.

Eligibility Criteria

Inclusion Criteria: * Aged 18-75 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective gynecological laparoscopic surgery * Normal cognitive function and able to complete postoperative pain assessments and use the postoperative analgesia device. Exclusion Criteria: * Severe cardiovascular, cerebrovascular, hepatic, or renal diseases, or other systemic diseases * Psychiatric disorders or long-term use of psychotropic drugs * History of chronic analgesic use or alcohol abuse * Use of analgesics within 48 h before surgery * Allergy to opioids or contraindications to opioid use * Speech or hearing impairment, or inability to complete pain assessments * Conversion to laparotomy or operative time \< 2 h during the study.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07913555). StuddyBuddy aggregates publicly available trial information.